2019 American Transplant Congress
mTOR Inhibitors Associated with Higher Cardiovascular Adverse Events – A Large Population Database Analysis
*Purpose: Our study aimed to compare the adverse events (AEs) of tacrolimus to mammalian target of rapamycin (mTOR) inhibitors in solid organ transplant patients.*Methods: Our…2019 American Transplant Congress
Increasing Time-in-Therapeutic Range of Tacrolimus is Associated with Superior Outcomes in Living Kidney Transplants
*Purpose: Tacrolimus-based regimens remain the backbone of maintenance immunosuppressive therapy in kidney transplant, and therapeutic drug monitoring of tacrolimus is necessary due to a narrow…2019 American Transplant Congress
CURATE.AI: Personalized Liver Transplant Tacrolimus Dosing
*Purpose: Transplant immunosuppressive regimens include multiple drugs with varying pharmacokinetics, metabolic pathways, and drug-drug interactions. This study aimed to use CURATE.AI, an artificial intelligence platform,…2019 American Transplant Congress
LCP-Tacrolimus (LCPT; Envarsus XR) Dosing Considerations in De Novo Kidney Transplant Recipients
*Purpose: Different initial dosing strategies were studied in Phase II/Phase III trials evaluating the pharmacokinetics, safety, and efficacy of LCPT in de novo kidney transplantation.…2019 American Transplant Congress
Impact of Once-Daily Tacrolimus on Trough Concentration Variability in Stable Adolescent and Young Adult Renal Transplant Recipients
Children's Hospital Colorado, Aurora, CO
*Purpose: High tacrolimus concentration variability (Vtac), likely influenced by medication non-adherence, is a risk factor for graft dysfunction and loss among renal transplant recipients (RTRs),…2019 American Transplant Congress
Functional Characterization of Orthotopic Hind-Limb Transplants in Rats
Comprehensive Transplant Center and Department of Surgery, Northwestern University, Chicago, IL
*Purpose: Vascularized composite allotransplantation (VCA) is a valid therapeutic option for patients with non-salvageable injuries such as severe burns or limb amputation. The immune response…2019 American Transplant Congress
CYP3A5 Genotype Had No Influence on Renal Function after Renal Transplantation
*Purpose: Tacrolimus metabolism rate has been reported to be associated with renal function after renal transplantation (Thölking et al., 2014); this study aimed to determine…2019 American Transplant Congress
Dosing and Exposure over 2 Years with LCP-Tacrolimus (LCPT) vs. Immediate-Release Tacrolimus (IR-Tac) in De Novo Kidney Transplantation
*Purpose: A prospective study demonstrated safe and efficacious use of LCPT in de novo kidney transplantation. This study aims to evaluate tacrolimus trough levels and…2018 American Transplant Congress
Clinical Significance of Tacrolimus Trough Level at the Early Period after Kidney Transplantation
Background:The stable immunosuppressant level at the early period after kidney transplantation (KT) is one of the most important factors to decide the prognosis of KT.…2018 American Transplant Congress
Tacrolimus and Isavuconazole Therapy: What about the Drug Interaction?
1Henry Ford Hospital, Detroit; 2Wayne State University, Detroit, MI.
Introduction:Isavuconazole (ISV) is a triazole antifungal that is often utilized in solid organ transplant recipients (SOTR) for the treatment of invasive aspergillosis and mucormycosis. Isavuconazole…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 14
- Next Page »